Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Rhabdomyoma is the most common fetal cardiac tumor, and its development is related to tuberous sclerosis. Fetalcardiac rhabdomyomas often spontaneously regress in utero or after birth, but large tumors can cause hemodynamicobstruction. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used as an immunosuppressantafter organ transplantation. The mTOR inhibitors are well-known to have anti-tumor activity, and they have beenused for the treatment of patients with tuberous sclerosis. In the current case, fetal cardiac rhabdomyoma wascompletely resolved in utero during oral sirolimus treatment in the mother with tuberous sclerosis. This case showsthat oral sirolimus therapy in pregnancy may be a treatment for multiple or large fetal cardiac rhabdomyomas.
Abstract
Rhabdomyoma is the most common fetal cardiac tumor, and its development is related to tuberous sclerosis. Fetalcardiac rhabdomyomas often spontaneously regress in utero or after birth, but large tumors can cause hemodynamicobstruction. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used as an immunosuppressantafter organ transplantation. The mTOR inhibitors are well-known to have anti-tumor activity, and they have beenused for the treatment of patients with tuberous sclerosis. In the current case, fetal cardiac rhabdomyoma wascompletely resolved in utero during oral sirolimus treatment in the mother with tuberous sclerosis. This case showsthat oral sirolimus therapy in pregnancy may be a treatment for multiple or large fetal cardiac rhabdomyomas.
참고문헌 (11)
- Barnes BT, "Maternal sirolimus therapy for fetal cardiac rhabdomyomas", N Engl J Med, 378, pp.1844~1845 (2018)
- Fesslova V, "Natural history and long-term outcome of cardiac rhabdomyomas detected prenatally", Prenat Diagn, 24, pp.241~248 (2004)
- Breathnach C, "Rapid regression of left ventricular outflow tract rhabdomyoma after sirolimus therapy", Pediatrics, 134, pp.e1199~e1202 (2014)
- Ninic S, "Successful use of sirolimus for refractory atrial ectopic tachycardia in a child with cardiac rhabdomyoma", Ann Noninvasive Electrocardiol, 22, pp.e12435~ (2017)
- Demir HA, "Everolimus : a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma", Pediatrics, 130, pp.e243~e247 (2012)
- Sasongko TH, "Rapamycin and rapalogs for tuberous sclerosis complex", Cochrane Database Syst Rev, 7, pp.CD011272~ (2016)
- Bader RS, "Fetal rhabdomyoma : prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex", J Pediatr, 143, pp.620~624 (2003)
- "Rapamune (sirolimus) oral solution and tablets" (2012), Wyeth Pharmaceuticals, Inc
- Briggs GG, "Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk" (2015), Wolters Kluwer
- Framarino-dei-Malatesta M, "Impact of mTOR-I on fertility and pregnancy : state of the art and review of the literature", Expert Rev Clin Immunol, 9, pp.781~789 (2013)
- Costanzo MR, "The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients", J Heart Lung Transplant, 29, pp.914~956 (2010)